Yi Larson
Officer at LianBio (LIAN)
Yi Larson has filed 14 insider reports with the SEC since February 2021, as director at Olema Pharmaceuticals, Inc. (OLMA), director at RayzeBio, Inc. (RYZB) and officer at LianBio (LIAN) and at 1 more company. Yi Larson made no open-market purchases or sales in the last 12 months. The latest filing, on June 23, 2026, reports grant or award at Olema Pharmaceuticals, Inc. (OLMA).
- Filings
- 14
- Companies
- 4
- Bought on market
- None
- Sold on market
- $3.8M
Companies where Yi Larson is an insider
| Company | Role | Shares held | Bought | Sold | Avg buy | Price now | Last filing |
|---|---|---|---|---|---|---|---|
| Directorsince April 2021 | $7.22 | Jun 23, 2026 | |||||
| Director | Feb 27, 2024 | ||||||
| Officer | 325,901 | Mar 31, 2023 | |||||
| Officer | 7,321 | $3.8M | Feb 10, 2021 |
Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record.
Every filing
- Jun 18, 2026OLMASEC Form 4 filed by Director Larson YiForm 4Grant or award
- Jun 11, 2025OLMASEC Form 4 filed by Director Larson YiForm 4Grant or award
- Jun 14, 2024OLMASEC Form 4 filed by Director Larson YiForm 4Grant or award
- Feb 26, 2024RYZBSEC Form 4 filed by Larson YiForm 4Sale back to the company
- Jun 16, 2023OLMASEC Form 4 filed by Larson YiForm 4Grant or award
- Mar 29, 2023LIANSEC Form 4 filed by Larson YiForm 4Grant or award
- Jan 20, 2023LIANSEC Form 4 filed by Larson YiForm 4Grant or award
- Jun 17, 2022OLMASEC Form 4 filed by Larson Yi (Amendment)Form 4Grant or award
- Jun 16, 2022OLMASEC Form 4 filed by Larson YiForm 4Grant or award
- Jun 9, 2021OLMASEC Form 4 filed by Larson YiForm 4Grant or award
- Apr 5, 2021OLMASEC Form 4 filed by Yi LarsonForm 4Grant or award
- Apr 5, 2021OLMASEC Form 3 filed by Yi LarsonForm 3New insider
- Feb 8, 2021TPTXSEC Form 4: Yi Larson was granted 4,617 units of Common Stock, increasing ownership by 171% to 7,321 unitsForm 4Grant or award
- Feb 2, 2021-$3.8MTPTXSEC Form 4: Yi Larson exercised 30,000 units of Common Stock at a strike of $54.03 and sold $3,801,918 worth of Common Stock (30,000 units at $126.73)Form 4Exercise or conversion of a derivativeOpen-market sale10b5-1 plan
Compare Yi Larson with
- Yi Larson vs Jason O'Byrne1 shared
- Yi Larson vs Cyrus Harmon1 shared
- Yi Larson vs Cynthia M Butitta1 shared
- Yi Larson vs J. Scott Garland1 shared
- Yi Larson vs Gorjan Hrustanovic1 shared
- Yi Larson vs Ian T Clark1 shared
Other insiders at the same companies
- Jason O'ByrneOLMA
- Cyrus HarmonOLMA
- Bvf Partners L P/ilOLMA
- Cynthia M ButittaOLMA
- J. Scott GarlandOLMA
- Gorjan HrustanovicOLMA
- Ian T ClarkOLMA
- Sandra HorningOLMA
- Prakash RamanOLMA
- Andrew RappaportOLMA
- G. Walmsley GrahamOLMA
- Kovacs Shane William CharlesOLMA
- Shawnte MitchellOLMA
- Sasha Lu AustinOLMA
- David C. MylesOLMA
- Naseem ZojwallaOLMA
Questions about Yi Larson
- What is Yi Larson's role at LianBio?
- Yi Larson reports to the SEC as officer at LianBio (LIAN), according to the latest filing on March 31, 2023. Yi Larson has also filed as director at Olema Pharmaceuticals, Inc. (OLMA), director at RayzeBio, Inc. (RYZB) and officer at Turning Point Therapeutics, Inc. (TPTX).
- How many shares does Yi Larson own?
- After the latest filing that states it, Yi Larson directly owned 325,901 shares of LianBio (LIAN) and 7,321 shares of Turning Point Therapeutics, Inc. (TPTX). Shares held through trusts, funds or family members are reported separately and are not counted here.
- Has Yi Larson bought or sold stock recently?
- The most recent open-market sale was on February 2, 2021: sold 30,000 shares of Turning Point Therapeutics, Inc. (TPTX) for $3.8M at an average of $126.73.
- How do I get alerts when Yi Larson files?
- Follow Yi Larson on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale.
From SEC Forms 3, 4, 5 and 144 filed by Yi Larson (SEC CIK 0001785987). Totals count each trade once, skipping amendments whose original is on file, from Feb 3, 2021 on. View on SEC EDGAR